Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer

Clinical trial NCT06659042 · RECRUITING

Trial details

NCT number: NCT06659042
Sponsor: Shanghai Chest Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Lung Cancer, Non-Small Cell

Start date: 2024-11-20
Primary completion: 2025-11-20
Enrollment: 32

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.